The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide could help reduce weight and hunger in obese, healthy women.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 41 people

Who can join Ages 25–60 · female only Healthy volunteers accepted.

Timeline Started 2007-04 · est. completion 2010-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00456885 ↗

Description as written by the study sponsor.

This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes. The study is 35 weeks long and includes 19 outpatient visits. Participants will receive exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither participants nor investigators will know whether exenatide or placebo is being administered. Participants will be started randomly on either exenatide or placebo. Our hypothesis is that treatment with exenatide will curb appetite and lead to weight loss and may lead to changes in energy expenditure.

Treatments tested

exenatide also known as Byetta Drug

5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
Placebo Drug

Twice daily injection of placebo

Main thing measured	Change in Weight
Sponsor	Beth Israel Deaconess Medical Center
Conditions studied	Obesity, Impaired Glucose Tolerance
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00456885 ↗